The purpose of this study was to perform an audit of quantitative values obtained from gamma camera renography in the UK. Ten patient image sequences representing normal and pathological renal function were obtained from archived studies and distributed to hospitals in the UK. Hospitals were asked to measure five parameters: relative function, renogram time-to-peak (left and right), and whole kidney mean transit time (left and right). Details of methodology, software used and operator experience were requested. This allowed the influence of operational factors on variations in reported values to be examined. A total of 180 responses from 81 hospitals were received. Values reported for the parameters, together with other details supplied, were entered into Excel and SPSS for statistical analysis. Histograms representing the distribution of values were produced for each parameter. The largest variations were found for mean transit time and occasionally for time-to-peak. The effect of factors was assessed using nonparametric statistical tests applied independently to each renogram. For all the parameters, the hospital, UK region, supplier, computer and software version influenced variations in the reported values. Algorithm and site of background region were influencing factors for relative function, the background subtraction method influenced time-to-peak, and curve smoothing influenced mean transit time.

No abstract

This study compares the clinical value of the breast cancer tumour makers CA549 and TPS, and their tandem use when one or both markers indicate abnormality. For 144 patients presenting with active disease, 33 were classified as Stage I, 37 as Stage II, 40 as Stage III and 34 as Stage IV. For these patients the sensitivity of CA549 using a cut-off of 10 U/ml was 27%, 32%, 42% and 79%, respectively. The sensitivity of TPS for each stage using a cut-off of 100 U/l was 12%, 22%, 28% and 73%, respectively. At these cut-off levels, 36%, 46%, 63% and 91% of patients, respectively, have either CA549 or TPS or both markers raised. For 161 patients with diagnosed benign breast disease, the specificity of marker levels was 96% for CA549, 88% for TPS and 84% for tandem use. CA549 is shown to be superior to TPS and this was confirmed by Receiver Operating Characteristic (ROC) analysis using variable threshold levels, with the areas under the curves for all stages combined being 0.74 +/- 0.03 (ISD) and 0.66 +/- 0.03, respectively. The corresponding area under the curve for tandem use (0.75 +/- 0.03) is marginally greater than for either individual marker, although the difference with respect to CA549 is statistically insignificant.

No abstract